{"id":666116,"date":"2023-09-04T19:30:01","date_gmt":"2023-09-04T19:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666116"},"modified":"2023-09-04T19:30:01","modified_gmt":"2023-09-04T19:30:01","slug":"idiopathic-pulmonary-fibrosis-ipf-market-poised-for-phenomenal-growth-during-the-forecast-period-202332-delveinsight-biogen-celgene-roche-galapagos-nv-fibrogen-medicinova-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-ipf-market-poised-for-phenomenal-growth-during-the-forecast-period-202332-delveinsight-biogen-celgene-roche-galapagos-nv-fibrogen-medicinova-novartis_666116.html","title":{"rendered":"Idiopathic Pulmonary Fibrosis (IPF) Market Poised for Phenomenal Growth During the Forecast Period (2023-32) – DelveInsight | Biogen, Celgene, Roche, Galapagos NV, FibroGen, MediciNova, Novartis"},"content":{"rendered":"
\n
\"Idiopathic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Idiopathic Pulmonary Fibrosis Market size in seven major markets was USD 3,167 million in 2021, which is further expected to increase by 2032 at a CAGR of 6.6% for the study period (2019\u20132032). The Idiopathic Pulmonary Fibrosis Market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapies assisted by an increase in the diagnosed prevalent population of Idiopathic Pulmonary Fibrosis in the 7MM and the improvement in diagnosis methodologies.<\/div>\n

DelveInsight’s “Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Idiopathic Pulmonary Fibrosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Idiopathic Pulmonary Fibrosis treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Idiopathic Pulmonary Fibrosis (IPF): An Overview<\/strong><\/p>\n

The term “idiopathic” refers to a condition that has no known cause. Scarring produces stiffness in the lungs, making breathing harder. The most prevalent type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). It is a lung illness that produces scarring (fibrosis).<\/p>\n

Scarring produces stiffness in the lungs, making breathing harder. IPF causes irreversible and progressive lung damage, which means it becomes worse over time. Certain drugs can help to slow it down in some circumstances. Lung transplantation is occasionally indicated for persons with IPF.<\/p>\n

There are several diagnostic tools available and the consensus guidelines have been well-defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like X-rays, but they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.<\/p>\n

Idiopathic Pulmonary Fibrosis (IPF) Market Key Facts<\/strong><\/p>\n